untitled

Size: px
Start display at page:

Download "untitled"

Transcription

1 19CRC/ T0 T1 T2 T3 T4 M0 N0 M1 19CRC N1 N2 N3 Stage 0 Stage I Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IIIC Stage IV Tis

2 19CRC/ Subtype of Breast Cancer by molecular marker ER+ ER- HER2+ Luminal B HER2 type HER2- Luminal A Basal like

3 19CRC/ p= (n=105) (n=185) (n=93) (Cancer 100:44-, 2004)

4 19CRC/

5 19CRC/ (n=2808) 1-3 (n=1201) 4-9 (n=504) (n=579) ( )

6 19CRC/ HER2 36 HER22

7 19CRC/ Lapatinib - Mechanism of Action Normal activation by ATP Activation blocked by lapatinib PI3K ATP Shc Grb2 Sos Ras Raf Lapatinib Akt MAPK P Akt MAPK Survival Pathway Proliferation Pathway Xia W, et al. Oncogene 2002;21: Rusnak DW, et al. Mol Cancer Ther 2001;1: Survival Pathway Proliferation Pathway Biology based medicine

8 19CRC/ Development of Adjuvant Chemotherapy for Breast Cancer Evolution of Adjuvant Chemotherapy 1970s Initial use of anthracyclines 1 st Generation 2 nd Generation 3 rd Generation 4 th Generation 1980s 1990s Anthracyclines Taxanes Monoclonal antibody therapy HER family / VEGF / TK inhibition CMF ACx4 FEC FAC ACx4Px4 CALGB 9344 NSABP B28 FE 100 C FASG 05 ACx4Px4(q2w) CALGB 9741 FECx3Tx3 PACS 01 TAC BCIRG 001 AC P (w or q3w) vs AC T (w or q3w) ECOG 1199?? TC? USO9735 Therapy based on genomic profile and molecular biomarkers Subtype of Breast Cancer by molecular marker ER+ ER- HR HER2 HER2+ Luminal B HER2 type HER2- Luminal A Basal like Subtype of Breast Cancer by molecular marker ER+ ER- ER HER2+ Luminal B HER2 type HER2- Luminal A Basal like

9 19CRC/ Adjuvant Treatment for a 2 x 2 Marker Model of Breast Cancer ER+ ER- HER2+ trastuzumab chemo endocrine trastuzumab chemo HER2- endocrine chemo chemo Subtype of Breast Cancer by molecular marker ER+ ER- HER2+ Luminal B HER2 type HER2- Luminal A Basal like Adjuvant Treatment for a 2 x 2 Marker Model of Breast Cancer ER+ ER- HER2+ trastuzumab chemo endocrine trastuzumab chemo HER2- endocrine chemo chemo

10 19CRC/ Lapatinib - Mechanism of Action Normal activation by ATP Activation blocked by lapatinib DESIGN 1: Completion of ALL (neo)adjuvant chemotherapy prior to targeted therapy Locally-determined HER2-positive invasive breast cancer Centrally-determined HER2+; ER and PgR Surgery, complete (neo)adjuvant anthracycline-based chemotherapy (selected from an approved list) ATP Shc Grb2 Sos Ras Lapatinib LVEF 50% Max 12 w PI3K Akt Raf MAPK P Akt MAPK Trastuzumab 3-weekly (For 52 weeks) Lapatinib (For 52 weeks) Trastuzumab Weekly (For 12 weeks) Washout (6 weeks) Lapatinib (34 weeks) Lapatinib + Trastuzumab 3-weekly (For 52 weeks) Survival Pathway Proliferation Pathway Survival Pathway Proliferation Pathway Xia W, et al. Oncogene 2002;21: Rusnak DW, et al. Mol Cancer Ther 2001;1: Patients with ER or PgR-positive tumours receive endocrine therapy selected accordingly to menopausal status; endocrine therapy will be started after the end of chemotherapy, will be administered concurrently with targeted therapies and will be planned for at least 5 years Radiotherapy if indicated Subtype of Breast Cancer by molecular marker ER+ ER- HER2+ Luminal B HER2 type HER2- Luminal A Basal like Triple Negative Metastatic Breast Cancer: A Phase 2, Multi-Center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C) With or Without BSI-201, A PARP Inhibitor

11 19CRC/

12 19CRC/ Emetic Risk Agent High(90%) Cisplatin Moderate (30 to 90%) CPA, Doxorubicin, Epirubicin Irinotecan Low (10 to 30%) Paclitaxel, Docetaxel, Mitoxantrone Methotrexate, Gemcitabine Fluorouracil, Mitomycin Trastuzumab Minimal(10%) Vinorelbine JCO 24:

13 19CRC/ CMF FEC docetaxel

14 19CRC/ Elasto-Gel (glycerin) Cold cap principle * - 20F (- 30 C) Direct contact protected Frozen 3 hours before use Hand Grade NAIL TOXICITY RESULTS Control (45 patients) Protected Hand (45 patients) 0 49 % 89 % 1 29 % 11 % 2 22 % 0 % p= (Wilcoxon test) Patients and Methods Japan Breast Cancer Research Group CYP3A4H2 CYP3A4 CYP3A4 H2 H2 Grade 2(HFS)(FE)

15 19CRC/ Results H2 p0.001 TC TC Taxol weekly

16 19CRC/ 屑 92 疼 Herceptin Trastuzumab Four Year Update of Cardiac Dysfunction on NSABP B-31: A Randomized Trial of AC->Paclitaxel vs. AC->Paclitaxel with Trastuzumab in HER2 Positive, Node Positive Operable Breast Cancer : ASCO Abstract 581,2006 Risk factors for increased risk of CHF identified: (1) Age > to 5.4% (2) Requirement for hypertension medications - 6.4% (3) Post AC LVEF values of 50-54% % (4) Age > 50 with post AC LVEF values of 50-54% %

17 19CRC/ A. Paul Lanchbury and Nassir Habboubi. Cancer Treatment Review GOT,GPT (IU/l) T.Bil (mg/dl) EC EC 4 TAM /8 12/10 1/7 2/10 2/24 3/

18 19CRC/

untitled

untitled 19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase

More information

<4D F736F F F696E74202D2094AD955C BD82BF82C482F F6E E63655B93C782DD8EE68

<4D F736F F F696E74202D2094AD955C BD82BF82C482F F6E E63655B93C782DD8EE68 Polysomy 17 in Breast Cancer 2009 年 10 月 15 日 たちてん web conference 前回提示した症例 58 歳閉経後女性 右 MMK(T4bN1M0 Stage IIIB) に対して H11.8 月 Bt+Mn+Ax 試行 His ; IDC, t= 58mm, n= 9/22, HG3, ER/PR/HER2 = -/+/0 Adj ; ECx6 TAM

More information

CSPOR CSPOR NEOS New primary Endocrine-therapy Origination Study 1 ~10%~ ~90%~ 2 CSPOR CSPOR ER/HER 3 N-SAS BC06 version CSPOR CSPOR St. Gallen

CSPOR CSPOR NEOS New primary Endocrine-therapy Origination Study 1 ~10%~ ~90%~ 2 CSPOR CSPOR ER/HER 3 N-SAS BC06 version CSPOR CSPOR St. Gallen NEOS New primary Endocrine-therapy Origination Study 1 ~10%~ ~90%~ 2 ER/HER 3 4 St. Gallen ER/HER 5 6 Low risk n0 2 cm Grade 1 ER(+) and/or PgR(+) and HER2(-) 35 Intermediate n0 risk 2 cm Grade 2-3 ER(-)/PgR(-)

More information

スライド 1

スライド 1 QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014

More information

橡

橡 TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1

More information

Microsoft PowerPoint - 薬物療法

Microsoft PowerPoint - 薬物療法 2007 年 6 月 30 日 ( 土曜日 ) 第 15 回日本乳癌学会教育セミナー Primary Breast Cancer の治療 - 薬物療法 - 渡辺亨 twatanab@oncoloplan.com 浜松オンコロジーセンター長 http://www.oncoloplan.com 乳癌集学的治療の開始の前に 治療目標 すべての患者で乳房温存術の達成 具体的対応 温存手術の安全性 有用性を説明

More information

untitled

untitled ( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m

More information

食道がん化学放射線療法後のsalvage手術

食道がん化学放射線療法後のsalvage手術 2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573

More information

卵巣癌の治療

卵巣癌の治療 K-net:2008.7.17 85 90 8 10 20 (FIGO) a (FIGO) b (FIGO) c (FIGO) a (FIGO) b (FIGO) c (FIGO) (FIGO) (FIGO) Risk factors Preventive factors Risk factors 35 PCO, Preventive factors? Relative risk

More information

日本消化器外科学会雑誌第30巻第3号

日本消化器外科学会雑誌第30巻第3号 Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment

More information

Microsoft PowerPoint - Primary Chemotherapy against Triple Negative Luminal B Operable Breast Cancer[読み取り専用]

Microsoft PowerPoint - Primary Chemotherapy against Triple Negative  Luminal B Operable Breast Cancer[読み取り専用] Primary Chemotherapy against Triple Negative & Luminal B Operable Breast Cancer 杏雲堂病院腫瘍内科河野勤 Randomised clinical studies addressing the sequence of anthracyclines and taxanes in early BC Wildiers et al.

More information

Microsoft PowerPoint - Luminalを考える

Microsoft PowerPoint - Luminalを考える 2010 年 2 月 25 日 ( 木曜日 ) 多地点 WEB CONFERENCE Luminals 乳癌の治療を考える Case for Discussion (1) 31 才閉経前未婚女性 右乳癌 T2 N0 M0 stage IIA 乳房温存術 + センチネルリンパ節生検 浸潤性乳管癌, ly (-), v (-), SLN 陰性 t: 12 16 mm grade 1 ER: 陽性 ( 染色陽性割合

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション * ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1

More information

3) Beresford SAA, Weiss NS, Voigt LF, et al: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461, 1997 4) Daly

More information

スライド 1

スライド 1 分子標的時代における病理診断の対応 : 乳癌 増田しのぶ 1, 3, 津田均 3, 鬼島宏 2, 秋山太 2, 3 1 日本大学医学部病態病理学系病理学分野 2 日本病理学会精度管理委員会 3 同上乳癌ワーキンググループ 目次 乳癌における標的分子 : ER, HER2 ER, PgR, HER2 免疫染色の現状 ER, PgR, HER2 免疫染色外部精度管理システム確立のために molecular

More information

NL16-1_0329

NL16-1_0329 No.16-1 March. 2012 JAMTTC News Letter http://jamttc.umin.jp/ Japanese Association for Molecular Target Therapy of Cancer 135-85503-8-31 TEL: 03-3520-0111 ext.5413 FAX: 03-3570-0484 ...1 JAMTTC2012...2...3...4...5

More information

Microsoft Word - 01マニュアル・入稿原稿p1-112.doc

Microsoft Word - 01マニュアル・入稿原稿p1-112.doc 4 54 55 56 ( ( 1994 1st stage 2nd stage 2012 57 / 58 365 46.6 120 365 40.4 120 13.0 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 4 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97

More information

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3

VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%

More information

20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of

More information

<4D F736F F F696E74202D F93FB8AE08A7789EF A837E B283293FA96DA816A95CF8D E >

<4D F736F F F696E74202D F93FB8AE08A7789EF A837E B283293FA96DA816A95CF8D E > 2009 年 7 月 4 日 ( 土曜日 ) 日本乳癌学会ランチョンセミナー 14 St.Gallen 2009 治療選択の考え方 - ホルモン療法編 - 話の内容 若年性乳癌患者の治療は間違っていた? St.Gallen 2009 カテゴリーからスレッショルドへ 注目! 新しい標的薬剤 PARP 阻害剤 1 CASE STUDY 31 才閉経前未婚女性 右乳癌 T2 N0 M0 stage IIA

More information

2015 Aug % HER2 8% ~ 40% HER3 35% ~ 100% EGFR HER EGFR Kiyose 5 FISH EGFR 4. 9% EGFR Cetuximab 2 VEGF EGFR EGFR II Lordick ~

2015 Aug % HER2 8% ~ 40% HER3 35% ~ 100% EGFR HER EGFR Kiyose 5 FISH EGFR 4. 9% EGFR Cetuximab 2 VEGF EGFR EGFR II Lordick ~ 950 CN 34-1206 /R ISSN 1009-2501 http / /www. cjcpt. com 2015 Aug 20 8 950-955 410006 1009-2501 2015 08-0950-06 2 EGFR 2 HER2 VEGF PI3K / mtor C-Met - PARP FGFR FGFR-1 MK-866 Rilotumumab Olaparib 2014

More information

Gynecologic Oncology Trial and Investigation Consortium GOTIC-002

Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 Gynecologic Oncology Trial and Investigation Consortium GOTIC-002 3 8 ...2...2...2...2...3...4...4...5...9...9...9...9...9... 13... 13... 13... 13... 13... 13... 13... 14... 14... 15... 15... 15...

More information

24 24 CTZ 5HT 3 (), (), () () () NK1, etc CTZchemoreceptor trigger zone () 5HT 3 5HT 3 7, (1), (2), (1), 15HT 3, ,,,( ), CDDP, () (CDDP) NSCLC PS 0-2 CDDP >50mg/m2 OND 8mg DEX 4mg R (n=530) OND 8mg DEX

More information

第122号.indd

第122号.indd -1- -2- -3- 0852-36-5150 0852-36-5163-4- -5- -6- -7- 1st 1-1 1-2 1-3 1-4 1-5 -8- 2nd M2 E2 D2 J2 C2-9- 3rd M3 E3 D3 J3 C3-10- 4th M4 E4 D4 J4 C4-11- -12- M5 E5 J5 D5 C5 5th -13- -14- NEWS NEWS -15- NEWS

More information

untitled

untitled 2008/04/27 1. 1 2 staticdynamics etc 3 Hedberg A, Carlberg EB, Forssberg H, Hadders-Algra M. Development of postural adjustments in sitting position during the first half year of life. Dev Med Child Neurol.

More information

サイトメトリー12-1.indd

サイトメトリー12-1.indd Cell Growth Inhibition and Apoptosis in Cancer Cells Kazuki Omoteyama, Shoichi Inoue and Alaa-eldin Salah-eldin Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth

More information

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11

2 The Bulletin of Meiji University of Integrative Medicine 3, Yamashita 10 11 1-122013 1 2 1 2 20 2,000 2009 12 1 2 1,362 68.1 2009 1 1 9.5 1 2.2 3.6 0.82.9 1.0 0.2 2 4 3 1 2 4 3 Key words acupuncture and moxibustion Treatment with acupuncture, moxibustion and Anma-Massage-Shiatsu

More information

Microsoft PowerPoint - Dr.Watanabe.ppt [互換モード]

Microsoft PowerPoint - Dr.Watanabe.ppt [互換モード] 第 5 回東海 北陸乳癌会議 乳癌初期治療の基本的考え 浜松オンコロジーセンター 腫瘍内科渡辺亨 twatanab@oncoloplan.com 基本的考え 局所療法 ( 術 放射線 ) と全 療法 ( 抗癌剤 ホルモン剤 分 標的薬剤 ) を適切に組み合わせ 再発を予防する 浸潤癌ならば局所療法だけでよい 浸潤癌ならば 微 遠隔転移 を伴う可能性 ( 確率 ) があるので全 治療の追加を考慮する

More information

untitled

untitled twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical

More information

10 年相対生存率 全患者 相対生存率 (%) (Period 法 ) Key Point 1 の相対生存率は 1998 年以降やや向上した 日本で

10 年相対生存率 全患者 相対生存率 (%) (Period 法 ) Key Point 1 の相対生存率は 1998 年以降やや向上した 日本で 151 10 年相対生存率 全患者 相対生存率 (%) 82 76 79 61 60 53 52 51 46 1993 1997 1998 2001 2002 2006 2002 2006 (Period 法 ) 44 40 43 Key Point 1 の相対生存率は 1998 年以降やや向上した 日本でパクリタキセル カルボプラチン併用療法が標準治療となった時期と一致する 0 1 2 3 4 5

More information

CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table

More information

Rinku General Medical Center

Rinku General Medical Center Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines

More information

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio 7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine

More information

untitled

untitled 1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21

More information

XFEL/SPring-8

XFEL/SPring-8 DEVELOPMENT STATUS OF RF SYSTEM OF INJECTOR SECTION FOR XFEL/SPRING-8 Takao Asaka 1,A), Takahiro Inagaki B), Hiroyasu Ego A), Toshiaki Kobayashi A), Kazuaki Togawa B), Shinsuke Suzuki A), Yuji Otake B),

More information

CHEMOTHERAPY APR. 1984

CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated

More information

92 adenocarcinoma SE ly2 v2 n0 pstage KRAS XX XX 2 1 mfolfox6 l-lv 300 / L-OHP 130 / 5-FU 600 / 5-FU 3,600 / FU/LV de Gramont

92 adenocarcinoma SE ly2 v2 n0 pstage KRAS XX XX 2 1 mfolfox6 l-lv 300 / L-OHP 130 / 5-FU 600 / 5-FU 3,600 / FU/LV de Gramont 92 91 95 2016 5-FU 1 1) 2) 3) 2) 2016 1 5 2016 3 4 FOLFIRI Bevacizumab Bev 5-FU NH3 1 NH 3 5-FU NH 3 Key words: 5-FU : NH 3 orotate phosphorylase OPRT thymidylate synthase TS dihydropyrimidine dehydrogenase

More information

QOL primary endpoint primary endpoint NSABP B-18 AC(60/600) surgery surgery AC(60/600) Primary end points: disease free survival NSABP B-18 primary ch

QOL primary endpoint primary endpoint NSABP B-18 AC(60/600) surgery surgery AC(60/600) Primary end points: disease free survival NSABP B-18 primary ch T T pc primary endpoint QOL primary endpoint primary endpoint NSABP B-18 AC(60/600) surgery surgery AC(60/600) Primary end points: disease free survival NSABP B-18 primary chemotherapy in breast cancer:

More information

CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection

More information

! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The

More information

特集 Folia Pharmacol. Jpn. 142 PI3K/mTOR 新規がん治療薬の研究開発2 要約 PI K phosphatidyl inositol -kinase /mtor mammalian target of rapamycin PI K Akt mtor mtorc mto

特集 Folia Pharmacol. Jpn. 142 PI3K/mTOR 新規がん治療薬の研究開発2 要約 PI K phosphatidyl inositol -kinase /mtor mammalian target of rapamycin PI K Akt mtor mtorc mto 特集 Folia Pharmacol. Jpn. 142 P3K/mTOR 新規がん治療薬の研究開発2 要約 P K phosphatidyl inositol -kinase /mtor mammalian target of rapamycin P K Akt mtor mtorc mtorc / P K/mTOR mtorc P K/mTOR 1. はじめに Bcr-Abl kinase multi

More information

*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combinati

*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combinati *4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combination with angiotensin II induced hyperten sion chemotherapy

More information

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin

More information

<95DB8C9288E397C389C88A E696E6462>

<95DB8C9288E397C389C88A E696E6462> 2011 Vol.60 No.4 p.332 338 Usefulness of regional education program for dietary salt reduction: Self-monitoring of urinary salt excretion Kenichiro YASUTAKE[1] Kayoko SAWANO[1] Shoko YAMAGUCHI[1] Hiroko

More information

202

202 201 Presenteeism 202 203 204 Table 1. Name Elements of Work Productivity Targeted Populations Measurement items of Presenteeism (Number of Items) Reliability Validity α α 205 α ä 206 Table 2. Factors of

More information

Microsoft PowerPoint - ASCO 1998-2012

Microsoft PowerPoint - ASCO 1998-2012 Chugai InvestigatorsʼMeeting on Breast Cancer in Chicago 2012 ASCO 1998-2012 から学ぶ抗 HER2 療法の進歩 浜松オンコロジーセンター腫瘍内科渡辺亨 twatanab@oncoloplan.com Neoadjuvant Adjuvant 1st Line Metastatic 2nd Line Metastatic 1998

More information

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

More information

EBM Reviews Ovid Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Revie

EBM Reviews Ovid   Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Revie EBM Reviews 2006 4 Ovid http://www.usaco.co.jp/products/ovid/ovidplatform.html Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Reviews CDSR Database of Abstracts of Reviews of Effectiveness

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション 第 21 回京都乳癌コンセンサス会議 テーマ HER2 陰性再発乳癌の抗がん薬治療 アンケート集計結果 1 回答いただいた御施設 (50 音順 ) 大阪赤十字病院 大津赤十字病院 加藤乳腺クリニック 関西医科大学附属枚方病院 菅典道クリニック 京都医療センター 京都市立病院 京都第一赤十字病院 京都大学医学部附属病院 倉敷中央病院 公立八鹿病院 沢井記念乳腺クリニック 滋賀県立成人病センター 静岡県立がんセンター

More information

indd

indd Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf

More information

Unknown

Unknown Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ

More information

1_2.eps

1_2.eps 第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075

More information

スライド 1

スライド 1 第 4 回 福岡大学病院と院外薬局との がん治療連携勉強会 タキサン 福岡大学メディカルホール 2011 年 7 月 20 日福岡大学呼吸器内科内野順治 本日の内容 タキサンが適応となる癌種について 肺癌 乳癌 卵巣癌に治療の考え方とエビデンス 治療レジメンの紹介 疾患別で投与用量 投与方法が異なる事がある 一般名ドセタキセル水和物パクリタキセル 商品名タキソテール注タキソール注 効能 効果 乳癌

More information

Ł\”ƒ/flwŁš6mm

Ł\”ƒ/flwŁš6mm P F GCR E A I A M A O D E D N P GCR I A transgenerational transmission Kempe, C. H. et al., 1962battered child syndrome ghost in nursery X X X X X Y G B E C A B D P F GCR E A I A M A O D E D N P GCR oppositional

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション 再発腫瘍の個別化医療 京都大学医学研究科標的治療腫瘍学講座 新倉直樹 乳癌の治療におけるバイオマーカー 原発腫瘍 Months/years 再発腫瘍 Months/years Progression ER PgR HER2 Ki67? ER PgR HER2 腫瘍の性格や治療選択が原発腫瘍もしくは再発腫瘍内で同じでいいのか? Abbreviations: ER, oestrogen receptor;

More information

スライド 1

スライド 1 日本肺がん学会 肺がん診療ガイドライン 病理病期 I II IIIA 期 術後補助化学療法 1 術後補助療法 Pubmed を用いて以下を検索 : Key words:lung cancer, adjuvant therapy, non small cell lung cancer Limitation: 期間 :2004/12/01-2011/08/31 言語 ;English 文献 ;Clinical

More information

平成13年度内分泌攪乱化学物質のヒトへの健康影響調査研究報告書

平成13年度内分泌攪乱化学物質のヒトへの健康影響調査研究報告書 . 1,3 4 5. 1 2 NB-1 MCF7 MEIC 1-3 4-6 NB-1 JCRB Japan Cancer Research Bank MCF ATCCAmerican Type Culture Collection 2 19994 212 11 PVDF.22µm 8 2 11 4 4 3 5 1 4 cellsml -1 96 4,6 NB-1 48 MCF7 24 4 5 48

More information

5 11 3 1....1 2. 5...4 (1)...5...6...7...17...22 (2)...70...71...72...77...82 (3)...85...86...87...92...97 (4)...101...102...103...112...117 (5)...121...122...123...125...128 1. 10 Web Web WG 5 4 5 ²

More information

Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi

Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi Clinical Study of Effect of Intrathecal Use of Alpha-tocopherol on Chronic Vasospasm Hirotoshi Sano, Motoi Shoda, Youko Kato, Kazuhiro Katada, Youichi Shinomiya and Tetsuo Kanno Department of Neurosurgery,

More information

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004

Web Stamps 96 KJ Stamps Web Vol 8, No 1, 2004 The Journal of the Japan Academy of Nursing Administration and Policies Vol 8, No 1, pp 43 _ 57, 2004 The Literature Review of the Japanese Nurses Job Satisfaction Research Which the Stamps-Ozaki Scale

More information

Development of a Mine in Andes Mountains, Peru by Yumisaburo NURAI The development of Huanzala Mine was started in October 1966 after the completion of prospecting and production began at 500M.T./day crude

More information

untitled

untitled NTT 143-8540 5-21-16 Tel 03-3762-4151 Fax: 03-5493-5417 E-mail health@med.toho-u.ac.jp URL http://jhmtokyo.umin.jp 2 5 6 7 8 9 10 13 17 25 31 32 33 35 38 41 91 115 3 4 9 NPO 1999 5300 DPC BSC 9 2009 2

More information

Title 多重構造音響連成場の振動解析制御 Author(s) 菅野, 秀 Citation Issue Date 2012-03-25 URL http://hdl.handle.net/10748/5587 DOI Rights Type Thesis or Dissertation Textversion publisher http://www.tmu.ac.jp/ 首都大学東京機関リポジトリ

More information

untitled

untitled Shinichiro Okamoto MD, PhD Keio University School of Medicine Tokyo Japan vincristine) Berberidaceae etoposide VP-16) MRD 10 12 PCR 10 10 10 8 10 6 10 4 10 2 ( CR) ( CR) AML Study n Ind Consol % 3

More information

化学療法

化学療法 第 60 回 医 療 者 がん 研 修 会 2015/9/17 もっと 知 りたい 膀 胱 癌 治 療 尿 管 癌 膀 胱 癌 の 化 学 療 法 広 島 市 立 広 島 市 民 病 院 泌 尿 器 科 副 部 長 弓 狩 一 晃 泌 尿 器 科 での 化 学 療 法 経 尿 道 的 投 与 経 静 脈 動 脈 的 投 与 膀 胱 癌 治 療 1 表 在 癌 経 尿 道 的 膀 胱 腫 瘍 切 除

More information

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date 1958-01 URL http://hdl.handle.net/2433/111559 Right Type Departmental Bulletin

More information

日本消化器外科学会雑誌第29巻第9号

日本消化器外科学会雑誌第29巻第9号 Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe

More information

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative

More information

第79回_プログラム.indd

第79回_プログラム.indd Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial

More information

振動充填燃料の粒子焼結試験実施計画書

振動充填燃料の粒子焼結試験実施計画書 C JNCTJ8410 2004-006 2004 3 ( ) UPRISE Nd 250mL 0.2 mol Nd Nd (FP)DF DOBA DOiBA NN'-2--1.6 mol/l NN'- -1.7 mol/l NN'-1.5 mol/l DOBA 1mol/L 3.5mol/L 2 NN'--1.7 mol/l NN' -1.5 mol/l ZrRu Ce DF 150 100 Sr

More information

æ æ2 \ R esults of Open Patch Tests in Control Solutions Containing Ammonium Thioglycollate or Cysteine Group Using Cold Permanent Wave 3 \ Results of

æ æ2 \ R esults of Open Patch Tests in Control Solutions Containing Ammonium Thioglycollate or Cysteine Group Using Cold Permanent Wave 3 \ Results of æ æ2 \ R esults of Open Patch Tests in Control Solutions Containing Ammonium Thioglycollate or Cysteine Group Using Cold Permanent Wave 3 \ Results of Patch Tests Using Cold Permanent Wave Solutions on

More information

Table 2 Cases of Nail Deformity Associated with upward Distortion of Distal Soft Tissue No. Age Sex Affected RegionsDuration Results M Both grea

Table 2 Cases of Nail Deformity Associated with upward Distortion of Distal Soft Tissue No. Age Sex Affected RegionsDuration Results M Both grea Table 2 Cases of Nail Deformity Associated with upward Distortion of Distal Soft Tissue No. Age Sex Affected RegionsDuration Results 1. 49 M Both great toes 2 years Cured after 4 months 2. 11 F Both great

More information

Core Ethics Vol. a

Core Ethics Vol. a Core Ethics Vol. CP CP CP Core Ethics Vol. a - CP - - Core Ethics Vol. CP CP CP b CP CP CP e f a c c c c c c CP CP CP d CP ADL Core Ethics Vol. ADL ADL CP CP CP CP CP CP CP,,, d Core Ethics Vol. CP b GHQ

More information

pp 427 438 2006 Dimensional Change Card Sort ****** ** 2005 9 30 2004 8 2002 4 Zelazo, P. D., Carter, A., Reznick, J. S. & Frye, D. 1997 10 2003 Zelaz

pp 427 438 2006 Dimensional Change Card Sort ****** ** 2005 9 30 2004 8 2002 4 Zelazo, P. D., Carter, A., Reznick, J. S. & Frye, D. 1997 10 2003 Zelaz Title 幼 児 の 実 行 機 能 の 発 達 過 程 : Dimensional Change C を 用 いたルールの 理 解 とその 使 用 に 関 する 検 討 Author(s) 浮 穴, 寿 香 ; 橋 本, 創 一 ; 出 口, 利 定 Citation 東 京 学 芸 大 学 紀 要. 総 合 教 育 科 学 系, 57: 427-438 Issue Date 2006-02-00

More information

IPDF.qxd

IPDF.qxd 127 S-1 + oxaliplatin Neoadjuvant Chemotherapy by S-1 + oxaliplatin for an Elderly Gastric Cancer Patient with Extensive Lymph Node Metastasis -A Case Report-. Hiroki Takeshita, Akinori Noguchi, Hiroyuki

More information

VOL.48 NO.5 Key words: locally advanced esophageal cancer, multimodality therapy, neo- adjuvant chemoradiotherapy

VOL.48 NO.5 Key words: locally advanced esophageal cancer, multimodality therapy, neo- adjuvant chemoradiotherapy VOL.48 NO.5 Key words: locally advanced esophageal cancer, multimodality therapy, neo- adjuvant chemoradiotherapy MAY 2000 VOL.48 NO.5 MAY 2000 Table 2. Adverse events Toxicity was defined according to

More information

Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on validated prognotic nomogram and risk group stratification system

Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on validated prognotic nomogram and risk group stratification system 弘前大学医学部泌尿器科学教室 腎癌術後フォローアップ プロトコール Since 2005.9 参考文献 Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on validated prognotic nomogram and risk

More information

Bull. of Nippon Sport Sci. Univ. 47 (1) Devising musical expression in teaching methods for elementary music An attempt at shared teaching

Bull. of Nippon Sport Sci. Univ. 47 (1) Devising musical expression in teaching methods for elementary music An attempt at shared teaching Bull. of Nippon Sport Sci. Univ. 47 (1) 45 70 2017 Devising musical expression in teaching methods for elementary music An attempt at shared teaching materials for singing and arrangements for piano accompaniment

More information

スライド 1

スライド 1 1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00

More information

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.

More information

症 例 :40 歳 女 性 5 年 前 (35 歳 ) 左 乳 腺 部 分 切 除 + 腋 窩 郭 清 ( 他 院 ) T2(3cm) N2(6/24) M0 StageIIIA ER+ PR+ HER2 断 端 陰 性 化 学 療 法 (ACx4+q1w Pacx4) 放 射 線 療 法 (60G

症 例 :40 歳 女 性 5 年 前 (35 歳 ) 左 乳 腺 部 分 切 除 + 腋 窩 郭 清 ( 他 院 ) T2(3cm) N2(6/24) M0 StageIIIA ER+ PR+ HER2 断 端 陰 性 化 学 療 法 (ACx4+q1w Pacx4) 放 射 線 療 法 (60G 第 12 回 日 本 乳 癌 学 会 九 州 地 方 会 教 育 セミナー < 治 療 > Luminalタイプ 転 移 再 発 乳 癌 の 治 療 久 保 真 九 州 大 学 病 院 乳 腺 外 科 (1) ( 第 一 外 科 ) 平 成 27 年 3 月 8 日 九 州 大 学 百 年 記 念 講 堂 症 例 :40 歳 女 性 5 年 前 (35 歳 ) 左 乳 腺 部 分 切 除 + 腋 窩

More information

乳癌化学療法

乳癌化学療法 乳癌薬物療法の昔と今 ~ 今までの治療から現在の治療について ~ 京都大学探索臨床腫瘍学講座特定助教森由希子 女性におけるがんの疫学 部位別癌年齢調整罹患率 部位別癌年齢調整死亡率 独立行政法人国立がん研究センターがん対策情報センター がん情報サービス http://ganjoho.jp/public/statistics/index.html, 2011 年代別乳がん罹患数 (2007 年 ) 9000

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション 第 14 回日本乳癌学会東北地方会 2017.3.4 教育セミナー 治療部門 担当工藤俊山形県立中央病院乳腺外科 skudo@ypch.gr.jp 筆頭演者の利益相反状態の開示 すべての項目に該当なし 2017.3.4 第 14 回日本乳癌学会東北地方会教育セミナー 治療部門 テーマ 実地臨床の現場でしばしば遭遇する 局所進行乳癌の治療 について 実例を通して検討する 局所進行乳癌 定義 Locally

More information

.K.C.h...C...ren

.K.C.h...C...ren 4 quality of life QOL QOL QOL 3 QOL 19 mmhg 16 mmhg 14 mmhg 1 2 7 20 30 QOL QOL QOL QOL QOL QOL QOL 4 1 1 1 2 1 2 3 1 2 4 2 2 1 2 2 2 2 1 2 3 QOL 3 2 1 1 5 1 1 2 1 Abraham Wise 1 Nd YAG 2 1 200 500 200

More information

_02戸沢.indd

_02戸沢.indd Akita J Med 43 : 79-86, 2016 15 1 1 1 1 2 2 3 4 4 1 2 3 4 received 19 July 2016, accepted 29 July 2016 Two cases of histological CR for squamous cell lung cancer with invasion to the pulmonary artery after

More information

錦鯉ナビ Vol.4

錦鯉ナビ Vol.4 5 3 14 Tomahawk of Kohaku 41cm 21 13 Kohaku 46cm Sakai Fish Farm 15 Kohaku 45cm of Symbol Star 18 Sister Symbol Kohaku 42cm of Legend of Love Garnet of Garnet Kohaku 44cm of 17 20 16 Kohaku 45cm Taisho

More information

日本化学療法学会雑誌第50巻第5号

日本化学療法学会雑誌第50巻第5号 paclitaxel 1 1 14 2 2 14 3 22 63 T4N3M1 stage Cisplatin CDDP paclitaxel TXL 1 grade 3 carboplatin CBDCA TXL 2 regimen 2 American Society of Clinical Oncology ASCO 1 regimen Key words: paclitaxel carboplatin

More information

ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship

More information

Jpn. J. Health & Med. Soc., 26(2) (2016)

Jpn. J. Health & Med. Soc., 26(2) (2016) 26 2 2016 娘の高年初産を経験した母親にとっての母娘関係 二世代のベビーブームに焦点をあてて Mother Daughter Relationship of Women Whose Daughters Carried Their First Baby at the Age of 35 or Over: Focus on Two Generations of Baby Boomers Keiko

More information

C/NC : committed/noncommitted

C/NC : committed/noncommitted C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a

More information

胆石症

胆石症 ,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic

More information

内分泌甲状腺外会誌 特集1 乳癌薬物療法の新展開 ペルツズマブ T-DM1 トラスツズマブ エムタンシン がん 感染症センター都立駒込病院乳腺外科 山下 年成 Pertuzumab, T -DM1 (Trastuzumab Emtansine) Department

内分泌甲状腺外会誌 特集1 乳癌薬物療法の新展開 ペルツズマブ T-DM1 トラスツズマブ エムタンシン がん 感染症センター都立駒込病院乳腺外科 山下 年成 Pertuzumab, T -DM1 (Trastuzumab Emtansine) Department 内分泌甲状腺外会誌 32 2 86-90 2015 特集1 乳癌薬物療法の新展開 ペルツズマブ T-DM1 トラスツズマブ エムタンシン がん 感染症センター都立駒込病院乳腺外科 山下 年成 Pertuzumab, T -DM1 (Trastuzumab Emtansine) Department of Surgery (Breast Oncology) Tokyo Metropolitan Komagome

More information

CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure p

CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure p CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure parameters during the diet and lifestyle improvement

More information

The nursing practices nurses consider important in the tertiary emergency rooms Kanako Honda'', Chizuko Miyake'', Midori Yao", Mikiko Kurushima", Kumiko Toyoda4 "The University of Shiga Prefecture, "Osaka

More information

21-07_後藤論文.smd

21-07_後藤論文.smd 2015; 21: 5866 Yoichi Goto: Current status and future perspective of cardiac rehabilitation in Japan. J Jpn Coron Assoc 2015; 21: 5866 I 1 1 3 1 2 3 QOL 2 Fig. 1 1 196070 AMI AMI 1980 AMI CABG comprehensive

More information

untitled

untitled 260 250 200 150 10 100 50 0 1960 1965 1970 1975 1980 1985 1985 1995 2000 2005 25% 56% 66% 60% 90 80 70 60 50 40 30 20 10 0 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1999 1990 2003 2005 2010 500,000 70,000 100,000

More information

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案) VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.

More information

02[021-046]小山・池田(責)岩.indd

02[021-046]小山・池田(責)岩.indd Developing a Japanese Enryo-Sasshi Communication Scale: Revising a Trial Version of a Scale Based on Results of a Pilot Survey KOYAMA Shinji and IKEDA Yutaka Toward exploring Japanese Enryo-Sasshi communication

More information

Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them

More information